Current Strategies and Future Directions of Antiangiogenic Tumor Therapy

Acta Biochimica et Biophysica Sinica

Volumn 35, Issue 10, 2003, Pages 873-880

  Zhang, Zi Lai ^a   Wang, Jin Hui ^a   Liu, Xin Yuan ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Angiogenesis; Antiangiogenesis tumor therapy; Tumor; Vasculature

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; CANCER VACCINE; CILENGITIDE; COMBRETASTATIN; D 2163; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; GANCICLOVIR; INTEGRIN; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 (1 METHYL 4 PIPERIDINYLMETHOXY) 4 QUINAZOLINAMINE; RAS FARNESYLTRANSFERASE INHIBITOR; SCH 221153; SEMAXANIB; TANOMASTAT; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; GENE THERAPY; HUMAN; IMMUNOTHERAPY; METASTASIS; NEUROTOXICITY; NONHUMAN; RADIOTHERAPY; SHORT SURVEY; TUMOR; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; GENE THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0347594382     PISSN: 05829879     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (64)

1. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst, 1998, 90(4): 273-286
2. Pluda JM. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies. Semin Oncol, 1997, 24(2): 203-218
3. Pepper MS. Manipulating angiogenesis. From basic science to the bedside. Arterioscler Thromb Vasc Biol, 1997, 17(4): 605-619
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86(3): 353-364
5. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein, 1996, 49(1-3): 117-137
6. Liekens S, de Clercq E, Neyts J. Angiogenesis: Regulators and clinical applications. Biochem Pharmacol, 2001, 61(3): 253-270
7. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs, 2000, 9(9): 2167-2177
8. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol, 1999, 9(3): 211-220
9. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell, 1996, 87(7): 1161-1169
10. Rusnati M, Presta M. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Int J Clin Lab Res, 1996, 26(1): 15-23
11. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J, 1997, 11(6): 457-465
12. Falcone DJ, McCaffrey TA, Haimovitz-Friedman A, Garcia M. Transforming growth factor-β1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor. J Cell Physiol, 1993, 155(3): 595-605
13. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, Wood J et al. Effects of PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res, 2000, 60(17): 4819-4824
14. Fong TA, Shawver LK, Sun L, Tang C, App H, Rowell TJ, Kim YH et al. SU 5416 is a potent and selective inhibitor of the vascularization, and growth of multiple tumor types. Cancer Res, 1999, 59(1): 99-106
15. Britten C, Rosen L, Kabbinavar F, Rosen P, Mulay M, Hernandez L. Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers. Proc ASCO, 2002, 21:28b
16. Drevs J, Esser N, Marme D. Effect of ZD6474, a VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis and vessel density in murine renal cell carcinoma. Proc AACR, 2002, 43: 1082
17. Manetti F, Corelli F, Botta M. Fibroblast Growth Factors and Their Inhibitors. Curr Pharm Des, 2000, 6(18): 1897-1924
18. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest, 1997, 100 (11 Suppl): S37-9
19. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor antibody in patients with metastatic cancer. Cancer Biother Radiopharm, 2001, 16(2): 125-132
20. 5 integrin receptor antagonist. Cancer Res, 2001, 61(5): 2232-2238
21. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer, 2003, 39(7): 917-926
22. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 1994, 265(5178): 1582-1584
23. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidker IJ. Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA, 1995, 92(10): 4562-4566
24. Clapp C, Martial JA, Guzman RC, Rentier-Delrue F, Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endrocrinology. 1993, 133: 1292-1299
25. O' Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 1994, 79(2): 315-28
26. O' Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997, 88(2): 277-85
27. Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC et al. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresss the growth of colon caecinomas in vitro. FASEB J, 1999, 13(1): 181-189
28. Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med, 1998, 188 (12): 2349-2356
29. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, Iruela-Arispe ML. METH-1, a human orthology of ADAMTS-1 and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem, 1999, 274(33): 23349-23357
30. Gupta SK, Hassel T, Singh JP. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA, 1995, 92(17): 7799-7803
31. O' Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science, 1999, 285(5435): 1926-1928
32. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Sasazuki T and Kerbel RS. Mutant ras oncogenes upregulate VEGF/VPF expression implications for induction and inhibition of tumor angiogenesis. Cancer Res, 1995, 55(20): 4575-4580
33. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human reneal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res, 1996, 56(10): 2299-2301
34. Kerbel RS, Viloria-Petit AM, Okada F, Rak JW. Establishing a link between oncogenes and tumor angiogenesis. Mol Med, 1998, 4(5): 286-295
35. Molema G, Meijer DK, de Leij LF. Tumor vasculature targeted therapies: Getting the players organized. Biochem Pharmacol, 1998, 55(12): 1939-1945
36. Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv. Cancer Res, 1999, 76: 1-20
37. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene, 2000, 19: 6122-6129
38. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B et al. Immunotheapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med, 2000, 6(10): 1160-1166
39. + cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther, 2000, 7(1): 43-52
40. Liau G, Su EJ, Dixon KD. Clinical efforts to modulate new blood vessel formation in the adult; a comparison of gene therapy versus conventional approaches. Drug Discov Today, 2001, 6(13): 689-97
41. Dehari H, Ito Y, Nakamura T, Kobune M, Sasaki K, Yonekura N, Kohama G et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther, 2003, 10(1): 75-85
42. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol, 2002, 20(18): 3906-3927
43. Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci, 2002, 23(12): 576-582
44. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature; the development of combretastatin. Lancet Oncol, 2001, 2(2): 82-87
45. Ruoslahti E, Rajotte D. An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol, 2000, 18:813-827
46. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet, 2000, 1(1): 48-56
47. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A et al. Genes expressed in human tumour endothelium. Science, 2000, 289(5482): 1197-1202
48. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature, 2001, 411(6835): 375-379
49. Xu X, Leo C, Jang Y, Chan E, Padilla D, Huang BC, Lin T et al. Dominant effector genetics in mammalian cells. Nat Genet, 2001, 27(1): 23-29
50. Huminiecki L, Gorn M, Suchting S, Poulsom R, Bicknell R. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics, 2002, 79(4): 547-552
51. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation, 2001, 69(2-3): 135-144
52. Drevs J, Laus C, Mendinger M, Schmidt-Gersbach C, Unger C. Antiangiogenesis: Current Clinical Data and Future Perspectives. Onkologie, 2002, 25(6): 520-527
53. Scappaticci FA, Smith R, Pathak A, Schloss D, Lum B, Cao Y, Johnson F et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther, 2001, 3(2): 186-196
54. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP et al. Potentiation of the atitumor effect of ionizing radition by brief concomitant exposures to angiostatin. Cancer Res, 1998, 58(24): 5686-89
55. Greenberger JS. Antitumor interaction of short course endostatin and ionizing radiation. Cancer J, 2000, 6(5): 279-281
56. Bergers G, Benjamin LE. Angiogenesis: Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 2003, 3(6): 401-410
57. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict theapy of transplantable tumors in mice. Cancer Metastasis Rev, 1998, 17(3): 279-284
58. Sternlicht MD, Bergers G et al. Matrix proteinases as emerging targets in anticancer therapy: Status and prospects. Emerging Therapeutic Targets, 2000, 4: 609-633
59. Augustin HG. Antiangiogenic tumor therapy: Will it work? Trends Pharmacol Sci, 1998, 19(6): 216-222
60. Kubek KA, Chan L, Frazier TG. Color Doppler flow as an indicator of nodal metastasis in solid breast masses. J Ultrasound Med, 1996, 15(12): 835-841
61. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging, 1997, 7(1): 68-74
62. Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W. The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res, 2003, 23(2C): 1859-1867
63. Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis, 2000, 21(3): 505-515
64. Matter A. Tumor angiogenesis as a therapeutic target. Drug Discovery Today, 2001, 6(19): 1005-1024